685 related articles for article (PubMed ID: 31560051)
1. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
Johnson SW; Brown SV; Priest DH
Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
[TBL] [Abstract][Full Text] [Related]
2. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
3. Oral Vancomycin as Secondary Prophylaxis for
Bao H; Lighter J; Dubrovskaya Y; Merchan C; Siegfried J; Papadopoulos J; Jen SP
Pediatrics; 2021 Aug; 148(2):. PubMed ID: 34330867
[TBL] [Abstract][Full Text] [Related]
4. Oral vancomycin prophylaxis for the prevention of
Babar S; El Kurdi B; El Iskandarani M; Haddad I; Imam Z; Alomari M; Myers J; Moorman J
Infect Control Hosp Epidemiol; 2020 Nov; 41(11):1302-1309. PubMed ID: 32594929
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of
Knight EM; Schiller DS; Fulman MK; Rastogi R
J Pharm Pract; 2020 Oct; 33(5):633-639. PubMed ID: 30744479
[TBL] [Abstract][Full Text] [Related]
6. Oral vancomycin prophylaxis against recurrent
Zacharioudakis IM; Zervou FN; Dubrovskaya Y; Phillips MS
Infect Control Hosp Epidemiol; 2020 Aug; 41(8):908-913. PubMed ID: 32539877
[TBL] [Abstract][Full Text] [Related]
7. Oral vancomycin for Clostridioides difficile prophylaxis in allogenic hematopoietic cell transplant.
Altemeier OJ; Konrardy KT
Transpl Infect Dis; 2022 Apr; 24(2):e13790. PubMed ID: 35014136
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a risk assessment model to predict infection with healthcare facility-onset Clostridioides difficile.
Tilton CS; Sexton ME; Johnson SW; Gu C; Chen Z; Robichaux C; Metzger NL
Am J Health Syst Pharm; 2021 Sep; 78(18):1681-1690. PubMed ID: 33954428
[TBL] [Abstract][Full Text] [Related]
9. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.
Stevens VW; Khader K; Echevarria K; Nelson RE; Zhang Y; Jones M; Timbrook TT; Samore MH; Rubin MA
Clin Infect Dis; 2020 Jul; 71(3):645-651. PubMed ID: 31504328
[TBL] [Abstract][Full Text] [Related]
10. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
11. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection.
Brown CC; Manis MM; Bohm NM; Curry SR
Ann Pharmacother; 2019 Apr; 53(4):396-401. PubMed ID: 30450942
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oral vancomycin prophylaxis for prevention of
Tariq R; Laguio-Vila M; Tahir MW; Orenstein R; Pardi DS; Khanna S
Therap Adv Gastroenterol; 2021; 14():1756284821994046. PubMed ID: 33747124
[TBL] [Abstract][Full Text] [Related]
13. Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of
Maraolo AE; Mazzitelli M; Zappulo E; Scotto R; Granata G; Andini R; Durante-Mangoni E; Petrosillo N; Gentile I
Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203786
[TBL] [Abstract][Full Text] [Related]
14. Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses.
Caroff DA; Menchaca JT; Zhang Z; Rhee C; Calderwood MS; Kubiak DW; Yokoe DS; Klompas M
Infect Control Hosp Epidemiol; 2019 Jun; 40(6):662-667. PubMed ID: 31030679
[TBL] [Abstract][Full Text] [Related]
15. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
[TBL] [Abstract][Full Text] [Related]
16. Implementation of routine Clostridioides difficile infection (CDI) primary prophylaxis in lung transplant recipients.
Fitzmaurice MG; Hohlfelder B; Srinivas P; Rudoni M; Brizendine KD; Budev M
Clin Transplant; 2023 Sep; 37(9):e15079. PubMed ID: 37477286
[TBL] [Abstract][Full Text] [Related]
17. Community-onset Clostridium difficile infection at a tertiary medical center in southern Taiwan, 2007-2015.
Tsai CS; Hung YP; Lee JC; Lee NY; Chen PL; Syue LS; Li MC; Li CW; Ko WC
J Microbiol Immunol Infect; 2018 Apr; 51(2):243-250. PubMed ID: 28089100
[TBL] [Abstract][Full Text] [Related]
18. Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update.
Slimings C; Riley TV
J Antimicrob Chemother; 2021 Jun; 76(7):1676-1688. PubMed ID: 33787887
[TBL] [Abstract][Full Text] [Related]
19. Clostridioides (Clostridium) difficile-associated disease: Epidemiology among patients in a general hospital in Saudi Arabia.
Al-Tawfiq JA; Rabaan AA; Bazzi AM; Raza S; Noureen M
Am J Infect Control; 2020 Oct; 48(10):1152-1157. PubMed ID: 32122671
[TBL] [Abstract][Full Text] [Related]
20. Shift to community-onset Clostridium difficile infection in the national Veterans Health Administration, 2003-2014.
Reveles KR; Pugh MJV; Lawson KA; Mortensen EM; Koeller JM; Argamany JR; Frei CR
Am J Infect Control; 2018 Apr; 46(4):431-435. PubMed ID: 29126751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
